Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Routbort

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
JCO Precision Oncology|October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialSarah Scollon, Sharon E Plon, Steven Joffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
The Journal of Molecular Diagnostics : JMD|February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical TrialChih-Jian Lih, Robin D Harrington, David J Sims, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective StudyLingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Therapeutic Advances in Medical Oncology|August 7, 2023
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimensHui Chen, Qingqing Ding, Laila Khazai, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2015
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functionsChi Young Ok, Zijun Y Xu-Monette, Ling Li, et al.
Blood Advances|October 25, 2019
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variantsXi Luo, Simone Feurstein, Shruthi Mohan, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
JCO Precision Oncology|October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialSarah Scollon, Sharon E Plon, Steven Joffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
The Journal of Molecular Diagnostics : JMD|February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical TrialChih-Jian Lih, Robin D Harrington, David J Sims, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective StudyLingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Therapeutic Advances in Medical Oncology|August 7, 2023
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimensHui Chen, Qingqing Ding, Laila Khazai, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2015
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functionsChi Young Ok, Zijun Y Xu-Monette, Ling Li, et al.
Blood Advances|October 25, 2019
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variantsXi Luo, Simone Feurstein, Shruthi Mohan, et al.
Pageof 18